Novo Nordisk's Buyback Machine Keeps Humming While Washington Slows a Hemophilia Launch
Published on 10/13/2026 at 14:11 | Editorial boerse-global.de
Novo Nordisk is pressing ahead with its share repurchase program even as the Danish drugmaker's equity sags under the weight of a difficult year. The company confirmed it has spent 10,247,270,869 DKK on buybacks to date under the up-to-15-billion-DKK framework unveiled in February, a signal that management intends to keep funneling capital back to shareholders.
The stock, however, tells a different story. Shares closed Monday at EUR 34.56, down roughly 22% since the start of the year, and sit about 12% below their 200-day moving average of EUR 39.29. The gap between the company's steady capital returns and the market's sour mood captures the central tension facing Novo Nordisk: a pipeline full of promise colliding with regulatory friction and cautious sell-side revisions.
A Hemophilia Filing Stuck in Regulatory Limbo
The most immediate headache comes from the FDA, which on October 2 extended its review of the Denecimig application for hemophilia A. The holdup stems from ongoing remediation work at a manufacturing site rather than any concern about the drug itself — the agency flagged no issues with clinical efficacy or safety data, and set no new decision timeline.
Novo Nordisk has stressed that the delay carries no consequences for its 2026 financial outlook. Assuming approval eventually lands, the company is targeting a US launch in the first half of 2027. Since the extension became public roughly two weeks ago, the shares have actually added 4.5%.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Analysts Trim Their Sights
Brokerages have nonetheless adjusted expectations. BMO Capital cut its price target to $40 while keeping a Market Perform rating, and Citi lowered its target to 296 DKK with a Neutral stance intact.
Semaglutide Data Lands on the EASD Stage
Against that cautious backdrop, Novo Nordisk used the EASD conference to showcase fresh evidence behind semaglutide, its flagship molecule. A retrospective study pitted a dose escalation to 2 milligrams of semaglutide against a switch to tirzepatide in adults with type 2 diabetes. The semaglutide arm came out ahead, showing a 6% lower risk of major cardiovascular events.
Additional presentations rounded out the picture. Patients migrating from injectable GLP-1 therapies to the oral Wegovy tablet shed an average of 4.1% of body weight after three months, according to an analysis drawing on data from the telehealth platform Ro. In a separate cohort with elevated liver fat, 88.5% of treated patients returned to normal levels after 72 weeks. Novo Nordisk also shared findings on CagriSema covering brain responses to food cues and visceral fat, though it explicitly characterized these as exploratory observations rather than established clinical results.
A $2.6 Billion Bet on China's Pipeline
Looking further out, the company moved to shore up future growth through external partnerships. On September 29, it signed an exclusive licensing deal with Jiangsu Hengrui Pharmaceuticals for HRS-1596, a once-weekly oral GLP-1/GIP candidate. The agreement grants Novo Nordisk development, manufacturing and commercialization rights everywhere outside mainland China, Hong Kong, Macau and Taiwan.
The contract carries a potential total value of up to $2.6 billion, including a $300 million upfront payment with the remainder tied to milestones and royalties. Completion is slated for the fourth quarter of 2026. Alongside the ongoing buyback, that pipeline expansion forms the backbone of Novo Nordisk's current corporate strategy as it navigates a demanding stretch in both its operations and its share price.
Ad
Novo Nordisk Stock: New Analysis - 13 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
